AstraZeneca Pharma India reappoints Revathy Ashok as Independent Director
Revathy Ashok has an Independent Consulting Practice, Iris Consulting working with mid and early stage companies.
AstraZeneca Pharma has informed that the members have approved the re‐appointment of Revathy Ashok, as an Independent Director for a second term of 5 years i.e., with effect from December 2, 2021 till December 1, 2026.
Revathy Ashok has an Independent Consulting Practice, Iris Consulting working with mid and early stage companies, helping them build value and scale. She is an angel investor with investmentsin over 15 start‐ups and works closely with her investee companies on various strategic matters.
She has had successful leadership experience of over thirty‐five years spanning variety of industries ‐ Private Equity, software and IT enabled services, manufacturing and infrastructure in Senior Management positions handling a wide variety of portfolios, namely, Capital Raising, Business Development, Finance, Commercial and other strategic general management functions.
Her immediate previous positions were Managing Director & Head Finance of Tishman Speyer in India and CFO of Syntel Inc, a Nasdaq listed IT major.
She currently serves on the Boards of leading listed companies and multinationals in India and chairs some of the Audit Committees. She has previously headed the CII Finance and Taxation Committee for Southern Region and served on the Governing Council of TiE Bangalore. Her social and philanthropic commitments are manifold.
In 2011, Revathy was nominated by CII as one of the top women achievers in Business in South India and in 2005, she was named as one of the 10 most powerful women in the Indian IT industry by Dataquest.
She has a bachelor’s degree in science from Mount Carmel College and is a gold medalist from the Indian Institute of Management, Bangalore.
At around 9:41 AM, Astrazeneca Pharma India was trading at Rs3,201 apiece down by Rs67.9 or 2.08% on Sensex.
Revathy Ashok has an Independent Consulting Practice, Iris Consulting working with mid and early stage companies, helping them build value and scale. She is an angel investor with investmentsin over 15 start‐ups and works closely with her investee companies on various strategic matters.
She has had successful leadership experience of over thirty‐five years spanning variety of industries ‐ Private Equity, software and IT enabled services, manufacturing and infrastructure in Senior Management positions handling a wide variety of portfolios, namely, Capital Raising, Business Development, Finance, Commercial and other strategic general management functions.
Her immediate previous positions were Managing Director & Head Finance of Tishman Speyer in India and CFO of Syntel Inc, a Nasdaq listed IT major.
She currently serves on the Boards of leading listed companies and multinationals in India and chairs some of the Audit Committees. She has previously headed the CII Finance and Taxation Committee for Southern Region and served on the Governing Council of TiE Bangalore. Her social and philanthropic commitments are manifold.
In 2011, Revathy was nominated by CII as one of the top women achievers in Business in South India and in 2005, she was named as one of the 10 most powerful women in the Indian IT industry by Dataquest.
She has a bachelor’s degree in science from Mount Carmel College and is a gold medalist from the Indian Institute of Management, Bangalore.
At around 9:41 AM, Astrazeneca Pharma India was trading at Rs3,201 apiece down by Rs67.9 or 2.08% on Sensex.
Comments